tiakis Biotech Advances Tiprelestat to Phase II Trial for Pulmonary Arterial Hypertension Following Positive Safety Data
核心洞察
tiakis Biotech has completed a comprehensive data package to advance Tiprelestat into Phase II clinical trials for pulmonary arterial hypertension (搜索) (PAH (搜索)), following successful completion of a 6-month GLP-tox study.
The preclinical safety study in rats demonstrated no adverse effects at any dose level, establishing a 20-fold safety window for the targeted human dose and supporting fixed doses of 5 mg/day and 10 mg/day subcutaneous administration.
Stanford University is expected to initiate the Phase II ATHENA trial in mid-2026, supported by a double-digit million dollar NIH grant and pending final FDA review.
tiakis Biotech AG announced the successful completion of a comprehensive data package to advance Tiprelestat into Phase II clinical trials for pulmonary arterial hypertension (搜索) (PAH (搜索)), marking a significant milestone for the first-in-class biological neutrophil elastase (搜索) inhibitor and BMPR2 (搜索) amplifier. The German clinical-stage biopharmaceutical company completed a critical 6-month GLP-tox study that reinforces the drug's favorable safety profile previously demonstrated across five clinical trials involving over 100 individuals.
Preclinical Safety Study Demonstrates Robust Therapeutic Window
The completed 6-month GLP-tox study in rats evaluated daily subcutaneous doses of Tiprelestat at 5 mg and 20 mg per kilogram of body weight for 180 days compared to a placebo control group. Clinical observations, safety laboratory results, gross necropsy results, and histopathology results revealed no adverse effects at any dose level, establishing a significant therapeutic window for safe dosing over 24 weeks in the upcoming Phase II PAH (搜索) trial.
The highest dose level tested corresponds to a Human Equivalent Dose (HED) providing a 20-fold safety window for the targeted dose in PAH (搜索) patients. These results strongly support the planned targeted exposure levels of Tiprelestat at fixed doses of 5 mg/day and 10 mg/day administered subcutaneously.
Phase II ATHENA Trial Timeline and Regulatory Progress
Stanford University is expected to initiate the Phase II ATHENA trial in mid-2026, pending final review by the U.S. FDA. The regulatory pathway has progressed favorably, with the FDA issuing a positive opinion on the study design in early 2025. In September 2025, Stanford University received a double-digit million dollar grant from the National Institutes of Health (NIH) to conduct the ATHENA trial.
Tiprelestat has secured orphan designations for PAH (搜索) in both Europe and the United States and is eligible for biologics exclusivity in the U.S. upon approval.
Addressing Critical Unmet Medical Need in PAH
Tiprelestat is being developed as an investigational disease-modifying therapy for PAH (搜索), demonstrating the ability to address underlying inflammation and potentially reverse vascular remodeling caused by this debilitating and fatal rare disease. Current registry data reveals the urgent medical need, with only a 57% five-year survival rate among diagnosed PAH patients.
"We are excited to have finalized a robust data package for the Phase II ATHENA trial of Tiprelestat in PAH (搜索)," said Martin Voss, Chief Executive Officer of tiakis. "Pulmonary arterial hypertension (搜索) remains an area of urgent unmet need, with current registry data showing a 5-year survival rate of only 57% of diagnosed PAH patients. We believe Tiprelestat holds significant promise as a potential disease-modifying therapy."
The company plans to engage with investors and biopharmaceutical companies during the JP Morgan Healthcare Conference in San Francisco from January 12-15, 2026.